title: Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain.
abstract: We disclose the design of a novel series of cyanoguanidines that are potent (IC(50) approximately 10-100 nM) and selective (> or = 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED(50) of 38 micromol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.
authors.affiliation: Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064-6101, USA. arturo.perezmedrano@abbott.com
authors.forename: Arturo
authors.initials: A
authors.lastname: Perez-Medrano
authors.forename: Diana L
authors.initials: DL
authors.lastname: Donnelly-Roberts
authors.forename: Prisca
authors.initials: P
authors.lastname: Honore
authors.forename: Gin C
authors.initials: GC
authors.lastname: Hsieh
authors.forename: Marian T
authors.initials: MT
authors.lastname: Namovic
authors.forename: Sridhar
authors.initials: S
authors.lastname: Peddi
authors.forename: Qi
authors.initials: Q
authors.lastname: Shuai
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Connie R
authors.initials: CR
authors.lastname: Faltynek
authors.forename: Michael F
authors.initials: MF
authors.lastname: Jarvis
authors.forename: William A
authors.initials: WA
authors.lastname: Carroll
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D015195:Drug Design; D055808:Drug Discovery; D006146:Guanidines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D009437:Neuralgia / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D058919:Purinergic P2 Receptor Antagonists; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000502:physiology; D058486:Receptors, Purinergic P2X7; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D006146:Guanidines; C546470:P2rx7 protein, rat; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; C004711:dicyandiamido